Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis-Reference-Cited by-同舟云学术

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis

Published:2023-04-14 Issue:4 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Wang Xiaoqin¹,Ma Yanfang²,Hui Xu³⁴,Li Meixuan³⁴,Li Jing³⁴,Tian Jinhui³⁴,Wang Qi⁵,Yan Peijing⁶,Li Jianfeng⁷,Xie Ping⁷,Yang Kehu³⁴,Yao Liang⁵

Affiliation:

1. Michael G DeGroote Institute for Pain Research and Care; McMaster University; Hamilton Canada

2. School of Chinese Medicine; Hong Kong Baptist University; Hong Kong Special Administrative Region China

3. Evidence-Based Medicine Center, School of Basic Medical Sciences; Lanzhou University; Lanzhou China

4. Evidence-Based Social Science Research Center, School of Public Health; Lanzhou University; Lanzhou China

5. Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences; McMaster University; Hamilton Canada

6. Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital; Sichuan University; Chengdu China

7. Department of Cardiology; Gansu Provincial Hospital; Lanzhou China

Publisher

Wiley

Subject

Pharmacology (medical)

Reference280 articles.

1. Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY);Agnelli;Journal of Thrombosis and Haemostasis,2013

2. Oral apixaban for the treatment of acute venous thromboembolism;Agnelli;New England Journal of Medicine,2013

3. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial;Agnelli;Canadian Journal of Cardiology,2014

4. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial;Agnelli;Journal of Thrombosis and Haemostasis,2015

5. Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism;Agnelli;Annals of Internal Medicine,2013

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High systemic inflammation response index level is associated with an increased risk of lower extremity deep venous thrombosis: a large retrospective study;Annals of Medicine;2023-08-21

2. How do oral direct thrombin inhibitors (DTI) compare with standard anticoagulation for the treatment of deep vein thrombosis?;Cochrane Clinical Answers;2023-05-29

3. How do oral factor Xa inhibitors compare with standard anticoagulation for the treatment of deep vein thrombosis?;Cochrane Clinical Answers;2023-05-29

4. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism;Cochrane Database of Systematic Reviews;2023-04-14

5. Research Progress in the Treatment of Unstable Angina Pectoris;Advances in Clinical Medicine;2023